EPIMINDER LIMITED (ASX: EPI)
Health care · News and insights
EPI: $0.270 -1.82% · MC: $61M
Latest EPI announcements
Announcement Insights
Epiminder Advances US Launch With Broader FDA Clearance And Reimbursement Support
Epiminder has added practical supports for a US commercial launch as its DETECT reimbursement study advances: FDA clearance now covers patients aged 12 and older, and Medicare’s 2027 outpatient payment rate for the implant procedure is about 13% above the 2026 rate. DETECT enrolment reached 100 by late October, ahead of the November target, with completion of enrolment of up to 210 still expected by the end of the first half of 2027; a five-year rolling Stratus partnership is intended to integrate Minder data into a platform serving more than 7,000 US clinicians and administrators. September-quarter operating cash outflow rose to about $10 million, while cash of about $65 million and no borrowings was expected to fund activities well into 2028.
Updated 17 Nov 2026, 09:27 AM Sydney time
Sources
Strategic partnership with leading US EEG providerCMS Increases Medicare Payment for the Minder System CY 2027Resignation of Chief Financial OfficerChange of AddressFY27 YTD operational update and AGM materialsMinder System Cleared for Patients 12 -75 Years of AgeResults of Annual General MeetingQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-17 · Health care
EPI: $0.270 -1.82% · MC: $61M
Epiminder has signed a five-year rolling partnership with US neurodiagnostics provider Stratus Neuro, extending an existing agreement supporting its DETECT reimbursement study. Minder’s long-term brain monitoring data will be integrated into the StratusEEG platform to support the study and the commercial launch of the next-generation system. Earlier this month, Epiminder said the US Medicare payment rate for the Minder implant procedure would rise by approximately 13% in 2027.
Updated 2026-11-17 12:18
Sources
Strategic partnership with leading US EEG providerComments
2026-11-06 · Health care
EPI: $0.265 +10.42% · MC: $61M
US Medicare has increased the national hospital outpatient payment for Epiminder’s Minder implant procedure by 13% for calendar 2027. The payment covers hospital procedure costs, including the device, and is adjusted for local wages; it is not revenue paid directly to Epiminder. The decision follows last week’s FDA clearance expanding Minder’s use to adolescents with drug-resistant epilepsy. Epiminder expects enrolment in its DETECT study to reach 125 participants by December, up from 100 in mid-October.
Updated 2026-11-06 12:06
Sources
CMS Increases Medicare Payment for the Minder System CY 2027Comments
2026-11-04 · Health care
EPI: $0.260 +1.96% · MC: $61M
Epiminder says Mark McLellan has resigned as Chief Financial Officer and Company Secretary to pursue an opportunity outside the company. He will remain in the role until February 2027 to support an orderly handover, while the company begins seeking a replacement.
Updated 2026-11-04 10:07
Sources
Resignation of Chief Financial OfficerComments
2026-11-02 · Health care
EPI: $0.250 -5.66% · MC: $61M
Epiminder Limited has changed its registered office and principal place of business to Level 19, 7 Spencer Street, Melbourne, effective today. Its shares fell around 6% on the day, alongside the update.
Updated 2026-11-02 16:11
Sources
Change of AddressComments
2026-10-30 · Health care
EPI: $0.265 +0.00% · MC: $61M
The FDA cleared Epiminder’s Minder system for patients aged 12 and older, expanding eligibility from adults aged 18 and above to include adolescents with drug-resistant epilepsy. Separately, DETECT enrolment reached 100 patients ahead of the company’s November target and is now past halfway towards its planned enrolment of up to 210; Epiminder says it remains on track to complete enrolment by the end of the first half of 2027. The company reported cash of approximately $65 million at September’s end, with no borrowings, and said this is expected to fund activities well into 2028.
Updated 2026-10-30 14:20
Sources
FY27 YTD operational update and AGM materialsMinder System Cleared for Patients 12 -75 Years of AgeResults of Annual General MeetingComments
2026-10-28 · Health care
EPI: $0.270 +1.89% · MC: $61M
Epiminder shares climbed nearly 6% to $0.28 by 12:31 pm after the epilepsy monitoring company reported approximately $65 million in cash and no borrowings at the end of September. The company said the funds would support its DETECT study and development of its next-generation Minder device well into 2028.
Net operating cash outflow rose to approximately $10 million from $8 million in the preceding quarter, as research and development and staff costs increased. Staff costs included bonuses for the previous financial year. Epiminder also paid approximately $4 million to its largest shareholder, Cochlear, for next-generation device research and development controlled by Epiminder management. The company plans to provide an operating update at its annual general meeting on 30 October.
Updated 2026-10-28 12:56
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments